Is IRadimed Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IRadimed Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued, with a P/E ratio of 39, a Price to Book Value of 8.54, and an EV to EBITDA of 30.68. In comparison to peers, IRadimed Corp. has a more attractive valuation than Artivion, Inc., which has a P/E ratio of -268.22, and BioLife Solutions, Inc., which also shows negative P/E.
The stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 33.51% compared to the S&P 500's 13.30%, and a remarkable 5-year return of 234.69% against the S&P 500's 91.29%. This strong performance reinforces the notion that IRadimed Corp. is currently undervalued in the market.